Skip to main content
. 2016 Nov 24;18:272. doi: 10.1186/s13075-016-1170-3

Fig. 1.

Fig. 1

Improvement in patients using etanercept, adalimumab or tocilizumab according to the Pediatric American College of Rheumatology (PedACR)30/50/70 and 90 criteria